7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Uremia D014511 33 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Rosso DA et al. Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. 2006 Pediatr. Res. pmid:16439593
Vidal K et al. Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. 2004 Pediatr. Res. pmid:15155868
Rianthavorn P et al. Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. 2010 Pediatr. Nephrol. pmid:20676692
Wasilewska A et al. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. 2010 Pediatr. Nephrol. pmid:20602239
Siomou E et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. 2011 Pediatr. Nephrol. pmid:21479768
Ketteler M et al. "Missing" inhibitors of calcification: general aspects and implications in renal failure. 2005 Pediatr. Nephrol. pmid:15549415
Swolin-Eide D et al. The novel bone alkaline phosphatase B1x isoform in children with kidney disease. 2006 Pediatr. Nephrol. pmid:16932897
Angelopoulos NG et al. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. 2007 Oct-Nov Pediatr Hematol Oncol pmid:17786784
Skordis N et al. Hormonal dysregulation and bones in thalassaemia--an overview. 2008 Pediatr Endocrinol Rev pmid:19337163
Ishii R et al. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. 2006 Pediatr Blood Cancer pmid:16358318
Quan J et al. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. 2012 Pathology pmid:22406484
Won KY et al. RANK signalling in bone lesions with osteoclast-like giant cells. 2011 Pathology pmid:21532526
Levidou G et al. TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. 2013 Pathology pmid:23277172
Chan MH et al. Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. 2005 Pathology pmid:15875734
Ikeda T et al. Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. 2003 Pathol. Int. pmid:12828610
Michou L et al. [Molecular analysis of Paget's disease of bone]. 2007 Apr-May Pathol. Biol. pmid:16884862
Pietrapertosa AC et al. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. 2009 Panminerva Med pmid:19352306
Gulseren A et al. Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. 2011 Panminerva Med pmid:21659972
D'Amore M et al. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. 2006 Panminerva Med pmid:17215793
Satoh K et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. 2001 Pancreas pmid:11590320
Heitzer E et al. IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer. 2012 Nov-Dec Pain Physician pmid:23159968
Cervellati C et al. Higher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia. 2016 Oxid Med Cell Longev pmid:26635910
Songia P et al. Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model. 2017 Oxid Med Cell Longev pmid:28261377
Kuczkowski J et al. [Molecular control of bone resorption in chronic otitis media with cholesteatoma]. 2010 Jul-Aug Otolaryngol Pol pmid:20873097
Hamed AA and Fayad JN Presence of otosclerosis and paget lesions in the same temporal bone. 2009 Otol. Neurotol. pmid:19779387
Jurado S et al. Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures. 2010 Osteoporos Int pmid:19436932
Sheng ZF et al. Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. 2009 Osteoporos Int pmid:18496637
Dobnig H et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. 2006 Osteoporos Int pmid:16435076
Kananen K et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? 2006 Osteoporos Int pmid:16437190
Nakashima A et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. 2011 Osteoporos Int pmid:20812007
Ulivieri FM et al. Increased osteoprotegerin in Italian haemodialysis patients. 2006 Osteoporos Int pmid:17019516
Jiang SD et al. Effects of spinal cord injury on osteoblastogenesis, osteoclastogenesis and gene expression profiling in osteoblasts in young rats. 2007 Osteoporos Int pmid:17036173
Findlay DM and Atkins GJ Relationship between serum RANKL and RANKL in bone. 2011 Osteoporos Int pmid:21850548
D'Amelio P et al. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. 2011 Osteoporos Int pmid:21116815
Li YF et al. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. 2012 Osteoporos Int pmid:21892678
Wheater G et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. 2011 Osteoporos Int pmid:21625887
Jørgensen L et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. 2010 Osteoporos Int pmid:19701599
Niu YB et al. The beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of action. 2012 Osteoporos Int pmid:22535190
Ferrari-Lacraz S and Ferrari S Do RANKL inhibitors (denosumab) affect inflammation and immunity? 2011 Osteoporos Int pmid:20571772
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Osteoporos Int pmid:11193242
Ominsky MS et al. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. 2007 Osteoporos Int pmid:17384898
Kahl KG et al. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. 2005 Osteoporos Int pmid:15300363
Mezquita-Raya P et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. 2005 Osteoporos Int pmid:15711777
Simpson CA et al. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. 2014 Osteoporos Int pmid:24927689
Indridason OS et al. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. 2005 Osteoporos Int pmid:15776220
Belaya ZE et al. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome. 2013 Osteoporos Int pmid:23358608
Fiore CE et al. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. 2005 Osteoporos Int pmid:15983730
Maïmoun L et al. In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels. 2011 Osteoporos Int pmid:21359671
Nakashima A et al. Osteoprotegerin and bone mineral density in hemodialysis patients. 2006 Osteoporos Int pmid:16604298
Riggs BL et al. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. 2003 Osteoporos Int pmid:12879223

Table of Content